Need and value of targeted immunosuppressive therapy in giant cell arteritis
Open Access
Abstract
Despite the heterogeneity of the giant cell arteritis (GCA) at the level of clinical manifestations and the cellular and molecular players involved in its pathogenesis, GCA is still treated with standardised regimens largely based on glucocorticoids (GC). Long-term use of high dosages of GC as required in GCA are associated with many clinically relevant side effects. In the recent years, the interleukin-6 receptor blocker tocilizumab has become available as the only registered targeted immunosuppressive agent in GCA. However, immunological heterogeneity may require different pathways to be targeted in order to achieve a clinical, immunological and vascular remission in GCA. The advances in the targeted blockade of various molecular pathways involved in other inflammatory and autoimmune diseases have catalyzed the research on targeted therapy in GCA. This article gives an overview of the studies with targeted immunosuppressive treatments in GCA, with a focus on their clinical value, including their effects at the level of vascular inflammation.Keywords
This publication has 49 references indexed in Scilit:
- Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trialAnnals of the Rheumatic Diseases, 2014
- Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia RheumaticaArthritis & Rheumatology, 2014
- Interleukin-1 blockade in refractory giant cell arteritisJoint Bone Spine, 2014
- A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effectsAnnals of the Rheumatic Diseases, 2008
- Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta‐analysisArthritis & Rheumatism, 2007
- The first case of a patient with neutropenia and giant-cell arteritis treated with rituximabClinical Rheumatology, 2007
- Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell ArteritisAnnals of Internal Medicine, 2007
- Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritisAnnals of the Rheumatic Diseases, 2005
- Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell ArteritisJournal of Experimental Medicine, 2004
- Tissue production of pro-inflammatory cytokines (IL-1 , TNF and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritisRheumatology, 2003